JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Handley, C. A.
Right arrow Articles by Moyer, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Handley, C. A.
Right arrow Articles by Moyer, J. H.
Journal of Pharmacology And Experimental Therapeutics, Vol. 110, Issue 3, 277-281, 1954
Copyright © 1954 by American Society for Pharmacology and Experimental Therapeutics

THE EFFECT OF A DIBENZAZEPINE DERIVATIVE (ILIDAR) ON RENAL FUNCTION

Carroll A. Handley 1 and John H. Moyer 1

1 Department of Pharmacology, Baylor University College of Medicine, Houston 25, Texas

The adrenergic blocking agent Ilidar (6-allyl-6,7-dihydro-5H-dibenz [c, e] azepine hydrochloride) may reduce the mean blood pressure considerably without depressing the glomerular filtration rate, renal plasma flow, or the maximal rate of tubular transport of glucose. In some experiments there was a significant increase in renal plasma flow indicating a sufficient reduction in renal vascular resistance to cause an augmented blood flow despite the hypotension.

Submitted on October 8, 1953






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1954 by the American Society for Pharmacology and Experimental Therapeutics.